menu
    • menu
    [{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Moleculin Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Annamycin","moa":"Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Moleculin Biotech","highestDevelopmentStatusID":"7","companyTruncated":"WPD Pharmaceuticals \/ Moleculin Biotech"},{"orgOrder":0,"company":"WPD Pharmaceuticals","sponsor":"Polish National Center for Research and Development","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Antibiotic","year":"2021","type":"Funding","leadProduct":"Annamycin","moa":"||Topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"WPD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"WPD Pharmaceuticals \/ Polish National Center for Research and Development","highestDevelopmentStatusID":"7","companyTruncated":"WPD Pharmaceuticals \/ Polish National Center for Research and Development"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Menarini","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Menarini"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Menarini","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"POLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MEN1703","moa":"PIM\/FLT3K","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ryvu Therapeutics \/ Menarini","highestDevelopmentStatusID":"7","companyTruncated":"Ryvu Therapeutics \/ Menarini"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1703

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Menarini

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ryvu Therapeutics' Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advan...

                            Details : MEN1703 (SEL24) is a first-in-class, dual PIM/FLT3 kinase inhibitor with a unique activity profile, which is investigated for the treatment of diffuse large B-cell lymphoma.

                            Product Name : SEL24

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 14, 2023

                            Lead Product(s) : MEN1703

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Menarini

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RVU120

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : BioNTech

                            Deal Size : $57.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million

                            Details : RVU120, a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors, is currently in phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome.

                            Product Name : RVU120

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 22, 2022

                            Lead Product(s) : RVU120

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : BioNTech

                            Deal Size : $57.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RVU120

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeuti...

                            Details : Preclinical data demonstrate that treatment with RVU120, a small molecule inhibitor of CDK8/19 kinases, in combination with an anti-CD20 antibody causes upregulation of LAMP1 surface level and increases NK cell cytotoxicity against CD20-positive positive...

                            Product Name : RVU120

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 10, 2022

                            Lead Product(s) : RVU120

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RVU120

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : European Investment Bank

                            Deal Size : $21.8 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            EIB to Support Ryvu Therapeutics’ Discovery, Research and Development of New Cancer Treatments with €22 Mi...

                            Details : Ryvu aims to address the clinical limitations of current treatments in oncology and provide patients with access to innovative therapies RVU120, for the treatment of haematologic and solid tumours.

                            Product Name : RVU120

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 17, 2022

                            Lead Product(s) : RVU120

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : European Investment Bank

                            Deal Size : $21.8 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            WPD Pharmaceuticals

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed

                            WPD Pharmaceuticals

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Annamycin,Cytarabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Polish National Center for Research and Development

                            Deal Size : $6.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate

                            Details : Annamycin is a "next generation" anthracycline, that has been shown to be less cardiotoxic compared to other anthracycline, such as doxorubicin, and to avoid multidrug resistance, so the use of Annamycin may not face the same dose limitations imposed on ...

                            Product Name : L-ANN

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            November 05, 2021

                            Lead Product(s) : Annamycin,Cytarabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Polish National Center for Research and Development

                            Deal Size : $6.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1703

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SEL24 (MEN1703) Clinical Data from DIAMOND-01 Trial to be Presented at ASCO and EHA Virtual Meetings 2021

                            Details : In the dose escalation part of DIAMOND-01 trial, SEL24(MEN1703) demonstrated a manageable safety profile up to the recommended dose (RD) of 125 mg/day, along with initial evidence of anti-leukemic activity in a single agent setting.

                            Product Name : SEL24

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 06, 2021

                            Lead Product(s) : MEN1703

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1703

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Menarini

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ryvu Begins Patient Dosing in Europe for Phase I/II DIAMOND-01 Trial of SEL24/MEN1703 to Treat AML

                            Details : First patient has been treated in Europe for the cohort expansion part of Phase II DIAMOND-01 clinical trial investigating SEL24/MEN1703, a first-in-class, oral dual PIM/FLT3 inhibitor, as single agent in Acute Myeloid Leukemia (AML).

                            Product Name : SEL24

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 16, 2020

                            Lead Product(s) : MEN1703

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Menarini

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed

                            Ryvu Therapeutics

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MEN1703

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ryvu Therapeutics Announces Abstracts Regarding Phase 1/2 Study of SEL120 and SEL24/MEN1703 Accepted for Prese...

                            Details : The poster concerning SEL24/MEN1703, is the first report on the successful completion of Phase I clinical study of SEL24/MEN1703 in Acute Myeloid Leukemia.

                            Product Name : SEL24

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 14, 2020

                            Lead Product(s) : MEN1703

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            WPD Pharmaceuticals

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed

                            WPD Pharmaceuticals

                            Poland arrow
                            Indo Livestock Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Annamycin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Moleculin Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            WPD Pharmaceuticals’ Annamycin Drug Candidate Meets Endpoint in Successful U.S. Phase 1 AML Trial With No Ev...

                            Details : The US Phase 1 trial shows the safety of Annamycin in a phase I trial setting when delivered to patients at or below the lifetime maximum anthracycline dose established by the FDA.

                            Product Name : L-ANN

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            April 23, 2020

                            Lead Product(s) : Annamycin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Moleculin Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth